Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07412990Recruiting

GRASS (Grass MATA MPL Real-world Assessment Study)

Role: collaborator

NCT05186025Active Not Recruiting

Tyrosine Allergoid Paediatric and Adult Study

Role: collaborator

NCT05455749Not ApplicableCompleted

Effect of holoBLG on Cat Allergic Patients

Role: collaborator

NCT04872868Completed

Long-term Effect of a 3-month Supplementation With Holo-BLG on House Dust Mite Induced Allergic Rhinoconjunctivitis

Role: collaborator

NCT04477382Completed

Impact of a Novel Immune Modulating Dietary Supplement on House Dust Mite Induced Allergic Rhinoconjunctivitis

Role: collaborator

NCT03127436Completed

Non-interventional Study to Assess the Tolerability and the Safety Profile of SCIT Therapy With Acarovac® Hausstaubmilbe

Role: collaborator

NCT03097432Completed

Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment

Role: collaborator

All 7 trials loaded